41 related articles for article (PubMed ID: 23903094)
1. Therapeutics: Disrupting a survival signal.
McCarthy N
Nat Rev Cancer; 2013 Sep; 13(9):608-9. PubMed ID: 23903094
[No Abstract] [Full Text] [Related]
2. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.
Neesse A; Frese KK; Bapiro TE; Nakagawa T; Sternlicht MD; Seeley TW; Pilarsky C; Jodrell DI; Spong SM; Tuveson DA
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12325-30. PubMed ID: 23836645
[TBL] [Abstract][Full Text] [Related]
3. Complete pathological response after chemotherapy alone in a patient with pancreatic adenocarcinoma.
Carbonell S; Espinosa J; Zarco A; de-Madaria E; de la Hoz J; Yuste A; Payá A; Lluís F
Pancreas; 2012 May; 41(4):657-9. PubMed ID: 22504386
[No Abstract] [Full Text] [Related]
4. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer.
Aikawa T; Gunn J; Spong SM; Klaus SJ; Korc M
Mol Cancer Ther; 2006 May; 5(5):1108-16. PubMed ID: 16731742
[TBL] [Abstract][Full Text] [Related]
5. Cavitary pulmonary metastases of pancreas cancer.
Tamura T; Nakazawa K; Kagohashi K; Kurishima K; Satoh H
J Gastrointest Cancer; 2013 Jun; 44(2):222-4. PubMed ID: 22875583
[No Abstract] [Full Text] [Related]
6. [nab-Paclitaxel as new therapeutic option for pancreatic cancer].
Michl P
Z Gastroenterol; 2013 Nov; 51(11):1329-30. PubMed ID: 24243574
[No Abstract] [Full Text] [Related]
7. A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling.
Cowan RW; Maitra A; Rhim AD
Gastroenterology; 2015 Dec; 149(7):1685-8. PubMed ID: 26526714
[No Abstract] [Full Text] [Related]
8. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure.
Chauhan VP; Boucher Y; Ferrone CR; Roberge S; Martin JD; Stylianopoulos T; Bardeesy N; DePinho RA; Padera TP; Munn LL; Jain RK
Cancer Cell; 2014 Jul; 26(1):14-5. PubMed ID: 25026209
[No Abstract] [Full Text] [Related]
9. Response to Chauhan et Al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and solids, measurement and meaning.
DelGiorno KE; Carlson MA; Osgood R; Provenzano PP; Brockenbough JS; Thompson CB; Shepard HM; Frost GI; Potter JD; Hingorani SR
Cancer Cell; 2014 Jul; 26(1):16-7. PubMed ID: 25026210
[No Abstract] [Full Text] [Related]
10. Irreversible electroporation: a novel pancreatic cancer therapy.
Weiss MJ; Wolfgang CL
Curr Probl Cancer; 2013; 37(5):262-5. PubMed ID: 24331180
[No Abstract] [Full Text] [Related]
11. The case for a stratified application of targeted agents against pancreatic cancer.
Bijlsma MF
EBioMedicine; 2021 May; 67():103344. PubMed ID: 33910122
[No Abstract] [Full Text] [Related]
12. Harnessing immune responses in the tumor microenvironment: all signals needed.
Le DT; Jaffee EM
Clin Cancer Res; 2013 Nov; 19(22):6061-3. PubMed ID: 24097857
[TBL] [Abstract][Full Text] [Related]
13. Use of a preclinical model of pancreas cancer to identify potential candidates for rapalogue therapy.
Takeuchi KK; Crawford HC
Gut; 2014 Sep; 63(9):1379-80. PubMed ID: 24966285
[No Abstract] [Full Text] [Related]
14. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
15. [Pancreatic cancer: a major challenge in oncology].
Fölsch UR; Schäfer H
Med Klin (Munich); 2004 Apr; 99(4):183-4. PubMed ID: 15085287
[No Abstract] [Full Text] [Related]
16. Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.
Lipkin S; Lee J; Imagawa D; Hewitt SM; Tucker C; Zell JA; Wong V; Garcia A; Gonzalez R; Della Zanna G; Richmond E; Rodriguez LM; Bigg M; Schnoll-Sussmans F; Meyskens F
Cancer Prev Res (Phila); 2011 Apr; 4(4):512-3. PubMed ID: 21464031
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma.
Engelhardt K; Riley C; Cooke L; Mahadevan D
Curr Drug Discov Technol; 2006 Dec; 3(4):231-43. PubMed ID: 17430101
[TBL] [Abstract][Full Text] [Related]
18. A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells.
Nishii Y; Yamaguchi M; Kimura Y; Hasegawa T; Aburatani H; Uchida H; Hirata K; Sakuma Y
Int J Oncol; 2015 Apr; 46(4):1781-7. PubMed ID: 25672256
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor.
Yang HH; Liu JW; Lee JH; Harn HJ; Chiou TW
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360896
[TBL] [Abstract][Full Text] [Related]
20. ASO Author Reflections: Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma-Predictors of Disease Progression and Performance Status Decline.
Paniccia A; Zureikat A
Ann Surg Oncol; 2020 Aug; 27(8):2972-2973. PubMed ID: 32124127
[No Abstract] [Full Text] [Related]
[Next] [New Search]
